Automated assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) diagnostics have recently come available. We compared the performance of the Elecsys® Anti–SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests. The seroconversion panel comprised of 120 samples from 13 hospitalized COVID-19 patients. For the sensitivity and specificity testing, samples from COVID-19 outpatients >15 days after positive nucleic acid amplification test (NAAT) result (n = 35) and serum control samples collected before the COVID-19 era (n = 161) were included in the material. Samples for the detection of possible cross-reactions were also tested. Based on our results, the SARS-CoV-2 antibodies can be quite reliably detected 2 weeks after NAAT positivity and 3 weeks after the symptom onset with both tests. However, since some COVID-19 patients were positive only with Elecsys®, the antibodies should be screened against N-antigen (Elecsys®) and reactive samples confirmed with S antigen (LIAISON®), but both results should be reported. In some COVID-19 patients, the serology can remain negative.

最近已经推出了用于检测2019年冠状病毒病（COVID-19）诊断中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的自动化检测方法。我们比较了Elecsys®Anti-SARS-CoV-2和LIAISON®SARS-CoV-2 S1 / S2 IgG测试的性能。血清转换小组包括来自13例住院的COVID-19患者的120个样本。对于敏感性和特异性测试，在阳性核酸扩增测试（NAAT）结果后超过15天（n  = 35）的COVID-19门诊患者的样本和在COVID-19时代之前收集的血清对照样本（n = 161）包含在材料中。还测试了用于检测可能的交叉反应的样品。根据我们的结果，两种测试均可在NAAT阳性后2周和症状发作后3周相当可靠地检测到SARS-CoV-2抗体。但是，由于某些COVID-19患者仅用Elecsys®呈阳性，因此应针对N抗原（Elecsys®）筛选抗体，并用S抗原（LIAISON®）确认反应性样品，但应报告两种结果。在某些COVID-19患者中，血清学可以保持阴性。